Answers are grounded in this paper and cite their sources.
BACKGROUND The rising global burden of type 2 diabetes mellitus and the side effects of synthetic DPP‐IV inhibitors have increased demand for food‐derived dipeptidyl peptidase‐IV (DPP‐IV) inhibitory peptides. Quinoa is a promising source of such bioactive peptides, while fungi from soybean paste exhibit high proteolytic activity. However, the use of fungi to produce quinoa‐derived DPP‐IV inhibitory peptides via fermentation remains unexplored. This study focused on isolating fungal strains from soybean pastes and preparing DPP‐IV inhibitory peptides from quinoa proteins. RESULTS Results suggested that 33 strains were isolated from 37 soybean paste samples, among which 16 strains exhibited high protease activity (>30 U mL −1 ). Among these, three strains, identified as Zygosaccharomyces sp. (a1), Cladosporium sp. (D1), and Talaromyces sp. (E2), yielded fermentates with the most potent DPP‐IV inhibitory activities, with median inhibitory concentration (IC 50 ) values of 4.55 ± 0.10, 4.36 ± 0.04, and 4.16 ± 0.04 mg mL −1 , respectively. The fermentation conditions of the three strains were optimized using single‐factor tests and orthogonal tests. After desalting and simulated gastrointestinal digestion, the product of strain a1 showed significantly enhanced DPP‐IV inhibitory activity, with marked inhibition in murine ileal tissue and Caco‐2 cells. Furthermore, the peptide VPQNFA was identified as the most potent DPP‐IV inhibitor (IC 50 = 190.84 ± 8.58 μmol L −1 ), acting as a competitive inhibitor and forming a stable VPQNFA–DPP‐IV complex via multiple hydrogen bonds. CONCLUSION These findings provide a novel strategy for preparing DPP‐IV inhibitory peptides via fungal fermentation, which holds potential as diabetes‐targeted functional food ingredients.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: